Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 70 years old
• People diagnosed with high-grade epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (specifically serous or endometrioid types)
• People who have received at least two rounds of platinum-based chemotherapy, where the cancer came back within six months of the last treatment, or where the cancer did not respond to platinum-based chemotherapy during at least two cycles
• People whose cancer can be measured on scans according to standard criteria (RECIST 1.1)
• People with a general health status rated 0 to 2 on a standard scale (meaning able to carry out daily activities with little to moderate limitation)
• People with a life expectancy of at least 12 weeks
• People who have had their BRCA1/2 gene mutation status confirmed through testing
• People who have never previously been treated with PARP inhibitor medications
• People whose heart is pumping at 50% or above on assessment
• People whose bone marrow, blood counts, liver, and kidney function meet specific minimum levels on lab tests (confirm exact values with trial site)
• People of childbearing age who agree to use effective contraception during the trial, have a negative pregnancy test, and are not breastfeeding
• People who have signed the trial's informed consent form

Who may not be able to join:

• People who have previously received PARP inhibitor treatment, unless they stopped due to cost or adherence reasons without the disease progressing, or unless they received only one prior PARP inhibitor (not fuzuloparib) as maintenance therapy for 12 months or more — and in either case, the last PARP inhibitor treatment must have been more than 6 months before joining the trial (confirm with trial site)
• People who have received radiotherapy to more than 20% of their bone marrow within the past week
• People who have had another cancer diagnosed in the past 5 years, except for fully treated cervical carcinoma in situ or certain non-melanoma skin cancers
• People with a serious ongoing infection that requires active treatment
• People with a known allergy or intolerance to fuzuloparib, arsenic trioxide, or the inactive ingredients in these medications
• People with moderate or severe peripheral neuropathy (nerve damage causing numbness or pain, rated grade 2 or higher on a standard scale)
• People whom the trial researchers consider unsuitable for participation for other reasons

Important: Always verify eligibility with the trial site directly before applying.